ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK plus non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)

被引：2
|
作者：
Solomon, B. J. [1 ]
Wu, Y-L. [2 ]
Dziadziuszko, R. [3 ,4 ]
Barlesi, F. [5 ,6 ]
Nishio, M. [7 ]
Ahn, J. S. [8 ]
Horinouchi, H. [9 ]
Hochmair, M. J. [10 ]
de Marinis, F. [11 ]
Migliorino, M. R. [12 ]
Kurochkin, A. [13 ]
Harputluoglu, H. [14 ]
Planchard, D. [5 ,6 ]
Korphaisarn, K. [15 ]
Han, J-Y. [16 ]
Lohmann, T. [17 ]
Gavaldon, A. Cardona [18 ]
Archer, V. R. [19 ]
Nowicka, M. [20 ]
Noe, J. [21 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Acad Med Sci, Oncol Dept,Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[3] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland
[4] Med Univ Gdansk, Early Phase Clin Trials Ctr, Gdansk, Poland
[5] Univ Paris Saclay, Dept Med Oncol, Villejuif, France
[6] Gustave Roussy, Villejuif, France
[7] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan
[8] Samsung Med Ctr, Dept Hematol & Oncol, Seoul, South Korea
[9] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[10] Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Dept Resp & Crit Care Med, Vienna, Austria
[11] European Inst Oncol IRCCS, Thorac Oncol Div, Milan, Italy
[12] San Camillo Forlanini Hosp, Pneumooncol Unit, Rome, Italy
[13] RCI Sumy Reg Clin Oncol Dispensary, Oncothorac Surg Dept, Sumy Region, Kharkiv Governo, Ukraine
[14] Inonu Univ, Dept Med Oncol, Med Fac, Turgut Ozal Med Ctr, Malatya, Turkiye
[15] Mahidol Univ, Dept Med, Fac Med, Siriraj Hosp, Bangkok, Thailand
[16] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[17] F Hoffmann La Roche Ltd, PD Oncol, Basel, Switzerland
[18] F Hoffmann La Roche Ltd, Data & Stat Sci, Basel, Switzerland
[19] Roche Prod Ltd, PDC, Welwyn Garden City, Herts, England
[20] F Hoffmann La Roche Ltd, Computat Sci, Basel, Switzerland
[21] F Hoffmann La Roche Ltd, Translat Med, Basel, Switzerland
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1206MO
引用
收藏
页码：S775 / S775
页数：1
相关论文
共 50 条
  • [31] Compliance with adjuvant chemotherapy for completely resected non-small cell lung cancer
    Lee, Hyun-Sung
    Kim, Moon Soo
    Lee, Jong Mog
    Kim, Heung Tae
    Zo, Jae Ill
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S480 - S480
  • [32] Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer
    Kassam, Farrah
    Shepherd, Frances A.
    Johnston, Michael
    Visbal, Antonio
    Feld, Ronald
    Darling, Gail
    Keshavjee, Shaf
    Pierre, Andrew
    Waddell, Thomas
    Leighl, Natasha B.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (01) : 39 - 43
  • [33] Toxicity and outcomes for patients with resected Non-Small cell lung cancer (NSCLC) who have received adjuvant chemotherapy in Bristol
    Ball, Jessica
    Ayre, Gareth
    Comins, Charles
    Dangoor, Adam
    Brooks, Helen
    Owadally, Waheeda
    LUNG CANCER, 2024, 190
  • [34] Adjuvant chemotherapy for radically resected non-small cell lung cancer - A retrospective analysis of 311 consecutively treated patients
    Dediu, M
    Horvat, T
    Tarlea, A
    Anghel, R
    Cordos, L
    Miron, G
    Lorga, P
    Alexandru, A
    Nistor, C
    Grozavu, C
    Savu, C
    LUNG CANCER, 2005, 47 (01) : 93 - 101
  • [35] Crizotinib safety profile in elderly and non-elderly patients (pts) with advanced ALK plus non-small cell lung cancer (NSCLC)
    Blackhall, F.
    Shaw, A. T.
    Jaenne, P. A.
    Kim, D. W.
    Wilner, K. D.
    Schnell, P.
    Polli, A.
    Besse, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S821 - S821
  • [36] Adjuvant or neoadjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC): How would staging affect the patients (pts) treated?
    Van Meerbeeck, J. P.
    Nicholson, M.
    Gilligan, D.
    Groen, H. J.
    Nankivell, M.
    Pugh, C.
    Stephens, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS PREVIOUSLY TREATED WITH ADJUVANT CHEMOTHERAPY
    Valdes, Mario
    Goss, Glenwood
    Nicholas, Garth
    Wheatley-Price, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S583 - S583
  • [38] Genetic landscape of ALK plus non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.
    Tan, Daniel Shao-Weng
    Kim, Dong-Wan
    Thomas, Michael
    Pantano, Serafino
    Wang, Ying
    Szpakowski, Sebastian Lukasz
    Yovine, Alejandro Javier
    Mehra, Ranee
    Chow, Laura Q.
    Sharma, Sunil
    Solomon, Benjamin J.
    Felip, Enriqueta
    Camidge, D. Ross
    Vansteenkiste, Johan F.
    Bitter, Hans
    Petruzzelli, Lilli M.
    Dugan, Margaret Han
    Shaw, Alice T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK plus ) non-small cell lung cancer (NSCLC) refractory to alectinib
    Ou, S-H. I.
    Nishio, M.
    Yoshida, T.
    Ahn, M-J.
    Mok, T. S. K.
    Kudou, K.
    Asato, T.
    Yang, H.
    Tong, X.
    Zhang, P.
    Yamamoto, N.
    Kim, E. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1014 - S1015
  • [40] Efficacy and safety of crizotinib in previously treated patients (Pts) with ALK plus advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y)
    Moro-Sibilot, D.
    Ahn, M-J.
    Halmos, B.
    Kim, D-W.
    Riely, G. J.
    Shaw, A. T.
    Yang, P-C.
    Lanzalone, S.
    Polli, A.
    Wilner, K. D.
    De Castro Carpeno, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 503 - 503
12345